. Author manuscript; available in PMC: 2019 Nov 15.

Published in final edited form as: Cancer. 2016 Jul 19;122(21):3327–3335. doi: 10.1002/cncr.30174

TABLE 6.

Time-to-Event Endpoints in the Response-Evaluable Population

Parameter	Statistic	Schedule 1 <1.25 mg/m² FIL or BTZ = 1.0 N = 26	Schedule 1, ≥1.25 mg/m² FIL and BTZ = 1.3 N = 19	Schedule 2 N = 10	Total Treate N = 55
Time on study, mo	No.	26	19	10	55
	Median	3.1	9.9	8.0	5.6
	95% CI	2.3–4.0	3.7–14.4	1.9–12.2	3.2–8.5
	Minimum-maximum	0.4–38.3^a	1.3–30.0	1.9–14.5	0.4–38.3^a
Time to first response (≥PR), mo	No.	1	8	2	11
	Median	33.9	1.3	0.7	1.0
	95% CI	NR	0.7–6.6	NR	0.7–6.6
	Minimum-maximum	33.9–33.9	0.7–10.6	0.7–0.7	0.7–33.9
Duration of response (≥PR), mo	No.	1	8	2	11
	Median	NR	17.2	8.7	14.1
	95% CI	NR	7.9-NR	5.2–12.2	5.2-NR
	Minimum-maximum	3.8^a–3.8^a	4.9^a–24.6^a	5.2–12.2	3.8^a–24.6^a

Abbreviations: 95% CI, 95% confidence interval; BTZ, bortezomib; FIL, filanesib; NR, not reached; PR, partial response.

Indicates censoring.